

Lukas Smolej

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400790/publications.pdf>

Version: 2024-02-01

139
papers

3,178
citations

172457
29
h-index

197818
49
g-index

147
all docs

147
docs citations

147
times ranked

5406
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 25530.	12.2	287
2	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
3	A cellular and spatial map of the choroid plexus across brain ventricles and ages. <i>Cell</i> , 2021, 184, 3056-3074.e21.	28.9	150
4	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	1.4	121
5	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , 2013, 24, 2119-2123.	1.2	107
6	Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. <i>Nucleic Acids Research</i> , 2015, 43, 2575-2589.	14.5	107
7	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1370-1379.	10.7	105
8	Mouse Model of Alagille Syndrome and Mechanisms of Jagged1 Missense Mutations. <i>Gastroenterology</i> , 2018, 154, 1080-1095.	1.3	92
9	Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. <i>Annals of Oncology</i> , 2017, 28, 218-227.	1.2	77
10	WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. <i>Nature Communications</i> , 2019, 10, 1498.	12.8	64
11	Fibroblast growth factor and canonical WNT/ β -catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 839-850.	3.8	56
12	Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9304-9309.	7.1	55
13	Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. <i>Nature Communications</i> , 2018, 9, 2301.	12.8	55
14	The connections of Wnt pathway components with cell cycle and centrosome: side effects or a hidden logic?. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2017, 52, 614-637.	5.2	51
15	Functional Analysis of Dishevelled-3 Phosphorylation Identifies Distinct Mechanisms Driven by Casein Kinase 1 α and Frizzled5. <i>Journal of Biological Chemistry</i> , 2014, 289, 23520-23533.	3.4	50
16	Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 459-469.	7.0	47
17	The natural compound Jatrophone interferes with Wnt/ β -catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. <i>PLoS ONE</i> , 2017, 12, e0189864.	2.5	46
18	Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. <i>British Journal of Pharmacology</i> , 2017, 174, 4701-4715.	5.4	45

#	ARTICLE	IF	CITATIONS
19	A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. <i>Molecular Neurodegeneration</i> , 2017, 12, 54.	10.8	44
20	Prothrombotic changes due to an increase in thyroid hormone levels. <i>European Journal of Endocrinology</i> , 2015, 172, 537-542.	3.7	43
21	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
22	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. <i>Lancet Haematology</i> , 2016, 3, e317-e329.	4.6	42
23	Targeting Casein Kinase 1 (CK1) in Hematological Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9026.	4.1	42
24	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1206-1218.	1.4	39
25	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , 2011, 117, 1817-1821.	1.4	37
26	Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 197, 264-270.	0.8	36
27	TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1560808.	12.2	36
28	The N-Terminal Part of the Dishevelled DEP Domain Is Required for Wnt/ β -Catenin Signaling in Mammalian Cells. <i>Molecular and Cellular Biology</i> , 2017, 37, .	2.3	34
29	WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer. <i>Theranostics</i> , 2020, 10, 537-552.	10.0	32
30	<sc>RNF</sc> 43 truncations trap <sc>CK</sc> 1 to drive niche-independent self-renewal in cancer. <i>EMBO Journal</i> , 2020, 39, e103932.	7.8	31
31	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
32	The planar cell polarity protein VANG-1/Vangl negatively regulates Wnt/ β -catenin signaling through a Dvl dependent mechanism. <i>PLoS Genetics</i> , 2018, 14, e1007840.	3.5	29
33	Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. <i>Blood</i> , 2014, 124, 21-21.	1.4	26
34	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1278-1282.	0.8	25
35	WNT5B in Physiology and Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 667581.	3.7	25
36	A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. <i>American Journal of Hematology</i> , 2016, 91, 900-906.	4.1	22

#	ARTICLE	IF	CITATIONS
37	Comparative phosphorylation map of Dishevelled 3 links phospho-signatures to biological outputs. <i>Cell Communication and Signaling</i> , 2019, 17, 170.	6.5	22
38	Comparative cell cycle transcriptomics reveals synchronization of developmental transcription factor networks in cancer cells. <i>PLoS ONE</i> , 2017, 12, e0188772.	2.5	22
39	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. <i>ELife</i> , 2021, 10, .	6.0	22
40	Dishevelled-3 conformation dynamics analyzed by FRET-based biosensors reveals a key role of casein kinase 1. <i>Nature Communications</i> , 2019, 10, 1804.	12.8	20
41	Venous thromboembolism in patients with chronic lymphocytic leukemia. <i>Thrombosis Research</i> , 2015, 136, 1082-1086.	1.7	19
42	Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. <i>Oncotarget</i> , 2016, 7, 62091-62106.	1.8	19
43	Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. <i>American Journal of Hematology</i> , 2015, 90, 417-421.	4.1	18
44	Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia. <i>Current Pharmaceutical Design</i> , 2012, 18, 3399-3405.	1.9	16
45	Î2-Arrestin Interacts with the Beta/Gamma Subunits of Trimeric G-Proteins and Dishevelled in the Wnt/Ca2+ Pathway in <i>Xenopus</i> Gastrulation. <i>PLoS ONE</i> , 2014, 9, e87132.	2.5	16
46	The tyrosine Y2502.39 in Frizzled 4 defines a conserved motif important for structural integrity of the receptor and recruitment of Dishevelled. <i>Cellular Signalling</i> , 2017, 38, 85-96.	3.6	16
47	Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, 313-324.	3.5	16
48	Analysis of binding interfaces of the human scaffold protein AXIN1 by peptide microarrays. <i>Journal of Biological Chemistry</i> , 2018, 293, 16337-16347.	3.4	16
49	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	1.4	16
50	Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling. <i>EMBO Molecular Medicine</i> , 2020, 12, e11739.	6.9	16
51	Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy. <i>Leukemia Research</i> , 2010, 34, e232-e234.	0.8	15
52	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. <i>European Journal of Haematology</i> , 2011, 87, 130-137.	2.2	15
53	Choroid Plexus: The Orchestrator of Long-Range Signalling Within the CNS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4760.	4.1	15
54	CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. <i>PLoS ONE</i> , 2020, 15, e0229170.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life. <i>Blood</i> , 2013, 122, 2877-2877.	1.4	15
56	A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples. <i>Leukemia Research</i> , 2011, 35, 889-898.	0.8	14
57	The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1009-1017.	4.1	14
58	Ofatumumab retreatment and maintenance in fludarabine- and refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2015, 170, 40-49.	2.5	14
59	COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. <i>Leukemia and Lymphoma</i> , 2017, 58, 70-79.	1.3	14
60	Protease associated domain of RNF43 is not necessary for the suppression of Wnt/ β -catenin signaling in human cells. <i>Cell Communication and Signaling</i> , 2020, 18, 91.	6.5	14
61	Plasma Concentrations of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Lymphoproliferative Disorders. <i>Acta Medica (Hradec Kralove)</i> , 2005, 48, 57-58.	0.5	14
62	Decreased $\langle \text{WNT} \rangle^3$ expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated $\langle \text{IGHV} \rangle$. <i>British Journal of Haematology</i> , 2016, 175, 851-859.	2.5	13
63	Dishevelled enables casein kinase 1-mediated phosphorylation of Frizzled 6 required for cell membrane localization. <i>Journal of Biological Chemistry</i> , 2018, 293, 18477-18493.	3.4	13
64	Activity of Smurf2 Ubiquitin Ligase Is Regulated by the Wnt Pathway Protein Dishevelled. <i>Cells</i> , 2020, 9, 1147.	4.1	13
65	MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. <i>Development (Cambridge)</i> , 2021, 148, .	2.5	13
66	Regulation of choroid plexus development and its functions. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 304.	5.4	12
67	Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, F33-F34.	0.4	11
68	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. <i>European Journal of Haematology</i> , 2013, 90, 479-485.	2.2	11
69	Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. <i>Blood Cancer Journal</i> , 2019, 9, 98.	6.2	11
70	Primary Cilia Formation Does Not Rely on WNT/ β -Catenin Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 623753.	3.7	10
71	Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. <i>Acta Medica (Hradec Kralove)</i> , 2005, 48, 57-8.	0.5	10
72	Angled Growth of the Dental Lamina Is Accompanied by Asymmetrical Expression of the WNT Pathway Receptor Frizzled 6. <i>Frontiers in Physiology</i> , 2017, 8, 29.	2.8	9

#	ARTICLE	IF	CITATIONS
73	Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 9.	2.7	9
74	Single-agent ibrutinib in RESONATE-2 ^a , ^c and RESONATE ^a , ^c versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	1.8	9
75	Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q ^a elite by the Czech CLL Study Group. <i>British Journal of Haematology</i> , 2021, 193, 769-778.	2.5	9
76	DUCT reveals architectural mechanisms contributing to bile duct recovery in a mouse model for Alagille syndrome. <i>ELife</i> , 2021, 10, .	6.0	9
77	Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010, 84, 513-517.	2.2	8
78	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. <i>Hematology</i> , 2010, 15, 210-214.	1.5	8
79	Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells. <i>Neoplasma</i> , 2011, 58, 140-145.	1.6	8
80	Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia. <i>Hematology</i> , 2012, 17, 268-274.	1.5	8
81	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 421-427.	0.9	8
82	WNT signalling: mechanisms and therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2017, 174, 4543-4546.	5.4	8
83	The Rho guanine nucleotide exchange factor Trio is required for neural crest cell migration and interacts with Dishevelled. <i>Development (Cambridge)</i> , 2020, 147, .	2.5	8
84	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. <i>Blood</i> , 2014, 124, 20-20.	1.4	8
85	Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2006, 91, 1432-3.	3.5	8
86	The reverse tetracycline-controlled transactivator rtTA2S-S2 is toxic in mouse embryonic stem cells. <i>Reproduction, Nutrition, Development</i> , 2003, 43, 477-486.	1.9	7
87	Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2008, 32, 395-400.	0.8	7
88	Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. <i>Apmis</i> , 2008, 116, 1058-1062.	2.0	7
89	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL ^a maintenance trial. <i>Cancer Medicine</i> , 2019, 8, 1401-1405.	2.8	7
90	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019, 79, 17-21.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <sc>GO&CLLEAR</sc> Study by the Czech <sc>CLL</sc> Study Group. Hematological Oncology, 2020, 38, 509-516.	1.7	7
92	Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge. Current Cancer Drug Targets, 2016, 16, 701-709.	1.6	7
93	Modern concepts in the treatment of chronic lymphocytic leukemia. Hematology, 2009, 14, 249-254.	1.5	6
94	<sc>ROR</sc>-based immunomagnetic protocol allows efficient separation of <sc>CLL</sc> and healthy B cells. British Journal of Haematology, 2016, 175, 339-342.	2.5	6
95	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. Cancers, 2021, 13, 3134.	3.7	6
96	Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group. Blood, 2010, 116, 2466-2466.	1.4	6
97	Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions. Current Cancer Drug Targets, 2016, 16, 710-720.	1.6	6
98	Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease. International Journal of Laboratory Hematology, 2008, 30, 259-260.	1.3	5
99	Practical approach to management of chronic lymphocytic leukemia. Archives of Medical Science, 2016, 2, 448-456.	0.9	5
100	Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies. Journal of Immunology Research, 2017, 2017, 1-8.	2.2	5
101	How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. Acta Medica (Hradec) Tj ETQq1 1 0.784314 rgBT /Overloc 0.5	0.5	5
102	Local Wnt signalling in the asymmetric migrating vertebrate cells. Seminars in Cell and Developmental Biology, 2022, 125, 26-36.	5.0	5
103	Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: More data needed. Leukemia Research, 2007, 31, 1763-1764.	0.8	4
104	Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?. Blood, 2008, 112, 2167-2167.	1.4	4
105	Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmacogenomics and Personalized Medicine, 2014, 8, 1.	0.7	4
106	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. Neoplasma, 2014, 62, 585-592.	1.6	4
107	Ten years&™ experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Leukemia and Lymphoma, 2015, 56, 2013-2018.	1.3	4
108	Roles of individual human Dishevelled paralogs in the Wnt signalling pathways. Cellular Signalling, 2021, 85, 110058.	3.6	4

#	ARTICLE	IF	CITATIONS
109	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. British Journal of Haematology, 2021, 193, 133-137.	2.5	4
110	Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Frontiers in Cell and Developmental Biology, 2022, 10, 838871.	3.7	4
111	Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using Locked Nucleic Acid-Modified, Fluorescently Labeled Hybridization Probes and Real-Time PCR Technology. Molecular Diagnosis and Therapy, 2007, 11, 325-335.	3.8	3
112	Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: Should we rely on surrogate markers?. Vaccine, 2008, 26, 1407.	3.8	3
113	Automatic Detection and Segmentation of Exosomes in Transmission Electron Microscopy. Lecture Notes in Computer Science, 2016, , 318-325.	1.3	3
114	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leukemia and Lymphoma, 2017, 58, 348-356.	1.3	3
115	On the road to optimized BTK inhibition in CLL. Blood, 2021, 137, 3313-3314.	1.4	3
116	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of <i>WNT5A</i> promoter and undetectable expression of <i>WNT5A</i> gene. Epigenetics, 2022, 17, 1628-1635.	2.7	3
117	LuminoCell: a versatile and affordable platform for real-time monitoring of luciferase-based reporters. Life Science Alliance, 2022, 5, e202201421.	2.8	3
118	The prognostic role of CLLU1 in chronic lymphocytic leukaemia. European Journal of Haematology, 2006, 77, 177-177.	2.2	2
119	Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: Rituximab as the treatment of choice?. Leukemia Research, 2007, 31, 267.	0.8	2
120	Phosphorylation-induced changes in the PDZ domain of Dishevelled 3. Scientific Reports, 2021, 11, 1484.	3.3	2
121	Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood, 2011, 118, 1793-1793.	1.4	2
122	Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection. Blood, 2011, 118, 2526-2526.	1.4	2
123	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. Blood, 2013, 122, 1645-1645.	1.4	2
124	Can We Pharmacologically Target Dishevelled: The Key Signal Transducer in the Wnt Pathways?. Handbook of Experimental Pharmacology, 2021, 269, 117-135.	1.8	2
125	Role of angiogenesis in chronic lymphocytic leukemia. Cancer, 2006, 107, 2742-2743.	4.1	1
126	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. Leukemia Research, 2010, 34, e140-e141.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia. <i>Lancet Oncology</i> , The, 2019, 20, 1478-1479.	10.7	1
128	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	3.4	1
129	Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2021, 193, 723-726.	2.5	1
130	Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7517-7517.	1.6	1
131	Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. <i>Leukemia Research Reports</i> , 2021, 16, 100274.	0.4	1
132	Why R-CHOP for first line treatment of chronic lymphocytic leukemia?. <i>International Journal of Laboratory Hematology</i> , 2007, 29, 478-479.	1.3	0
133	Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle. <i>British Journal of Haematology</i> , 2020, 190, 815-816.	2.5	0
134	Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using LNA-Modified Fluorescently Labeled Probes and Real-Time PCR Technology.. <i>Blood</i> , 2006, 108, 2331-2331.	1.4	0
135	Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro. <i>Blood</i> , 2008, 112, 3795-3795.	1.4	0
136	Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4629-4629.	1.4	0
137	The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. <i>Blood</i> , 2012, 120, 4603-4603.	1.4	0
138	Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5298-5298.	1.4	0
139	Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. <i>Onkologie (Czech) Tj</i> ETQq1 1 0.784314 rgBT ₀ /Overlock	0.1	0